{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:16:27Z","timestamp":1761174987324,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cmi.2023.04.018","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T20:16:36Z","timestamp":1682194596000},"page":"1114-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Which trial do we need? Comparison of 7 versus 14\u00a0days of antibiotic therapy for ventilator-associated pneumonia due to highly resistant gram-negative bacteria"],"prefix":"10.1016","volume":"29","author":[{"given":"Imad M.","family":"Tleyjeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.04.018_bib1","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.04.018_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/cid\/ciac784","article-title":"Less is more? Antibiotic treatment duration in Pseudomonas aeruginosa ventilator-associated pneumonia","volume":"76","author":"Albin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib4","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/cid\/ciac809","article-title":"Less is more: a 7-day course of antibiotics is the evidence-based treatment for Pseudomonas aeruginosa ventilator-associated Pneumonia","volume":"76","author":"Metersky","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101880","article-title":"Comparison of a short versus long-course antibiotic therapy for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials","volume":"58","author":"Daghmouri","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2023.04.018_bib6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/antibiotics9100719","article-title":"Relationship between virulence and resistance among gram-negative bacteria","volume":"9","author":"Cepas","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2023.04.018_bib7","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib8","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A\u00a0randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib11","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.04.018_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European society of clinical microbiology and infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.018_bib13","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial","volume":"323","author":"von Dach","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2023.04.018_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cmi.2022.08.026","article-title":"Use of biomarkers to individualize antimicrobial therapy duration: a narrative review","volume":"29","author":"Scott","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.018_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cmi.2022.08.007","article-title":"Shorter antibiotic courses in the immunocompromised: the impossible dream?","volume":"29","author":"Imlay","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.04.018_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00134-022-06690-5","article-title":"Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial","volume":"48","author":"Bougl\u00e9","year":"2022","journal-title":"Intensive Care Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2300191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:34:05Z","timestamp":1761118445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2300191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1198743X2300191X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.04.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? Comparison of 7 versus 14\u00a0days of antibiotic therapy for ventilator-associated pneumonia due to highly resistant gram-negative bacteria","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}